Novel possibility of vitreomacular traction treatment

What is it about?

The aim of this retrospective study was to evaluate visual and structural outcomes in patients treated with ocriplasmin because of symptomatic vitreomacular traction. Analysis was conducted on 16 patients treated with the ocriplasmin intravitreal injection because of vitreomacular traction in 12 cases and vitreomacular traction with macular hole in 4 cases. The study included 10 phakic and 6 pseudophakic patients. The analysis was based on ophthalmological examinations carried out before and after intravitreal injection. The fundamental outcome of VMT release was achieved in 12 patients. In the phakic patients group 8 achieved successful nonsurgical release of VMT. In the pseudophakic patients group in 4 patients there occurred VMT resolution. The increase of BCVA was observed in 13 out of 16 patients. No change from baseline vision was observed in 3 patients. Intravitreal injection of ocriplasmin represents a novel treatment option in the management of patients with symptomatic vitreomacular disorders. This is efficient and safe method with minimum frequency of adverse events.

Featured Image